{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:01:55Z","timestamp":1790913715386,"version":"4.1.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2008,12,20]],"date-time":"2008-12-20T00:00:00Z","timestamp":1229731200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2009,1]]},"DOI":"10.1007\/s12185-008-0230-0","type":"journal-article","created":{"date-parts":[[2008,12,19]],"date-time":"2008-12-19T03:29:48Z","timestamp":1229657388000},"page":"14-23","source":"Crossref","is-referenced-by-count":95,"title":["Chronic myeloid leukemia in Asia"],"prefix":"10.1007","volume":"89","author":[{"given":"Wing Y.","family":"Au","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscilla B.","family":"Caguioa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Chuah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Szu Chun","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saengsuree","family":"Jootar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Wook","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Il-Young","family":"Kweon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William M.","family":"O\u2019Neil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tapan K.","family":"Saikia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,12,20]]},"reference":[{"key":"230_CR1","unstructured":"North American Association of Central Cancer Registries (2007) North American age-specific invasive cancer incidence rates, chronic myeloid leukemia, 2000\u20132004. http:\/\/www.cancer-rates.info\/naaccr\/."},{"issue":"6","key":"230_CR2","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3747\/co.v13i6.124","volume":"13","author":"P Laneuville","year":"2006","unstructured":"Laneuville P, Barnett MJ, Belanger R, et al. Recommendations of the Canadian consensus group on the management of chronic myeloid leukemia. Curr Oncol. 2006;13(6):201\u201321.","journal-title":"Curr Oncol"},{"issue":"6","key":"230_CR3","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","volume":"108","author":"M Baccarani","year":"2006","unstructured":"Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006;108(6):1809\u201320.","journal-title":"Blood"},{"key":"230_CR4","unstructured":"National Comprehensive Cancer Network. Chronic myelogenous leukemia. Version 2. Fort Washington: National Comprehensive Cancer Network; 2007."},{"key":"230_CR5","first-page":"5","volume":"26","author":"B Arora","year":"2005","unstructured":"Arora B, Kumar L, Kumaru M, Sharma A, Wadhwa J, Kochupillai V. Therapy with imatinib for chronic myeloid leukaemia. Ind J Med Paediatr Oncol. 2005;26:5\u201318.","journal-title":"Ind J Med Paediatr Oncol"},{"issue":"6","key":"230_CR6","first-page":"281","volume":"24","author":"H Jiang","year":"2003","unstructured":"Jiang H, Chen S, Jiang B. Treatment of 54 chronic myelogenous leukaemia with Glivec. Zhonghua Xue Ye Xue Za Zhi. 2003;24(6):281\u20135.","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"5","key":"230_CR7","first-page":"255","volume":"19","author":"L Kumar","year":"2006","unstructured":"Kumar L. Chronic myelogenous leukaemia (CML): an update. Natl Med J India. 2006;19(5):255\u201363.","journal-title":"Natl Med J India"},{"key":"230_CR8","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1002\/cncr.20922","volume":"103","author":"T Lahaye","year":"2005","unstructured":"Lahaye T, Riehm B, Berger U. Response and resistance in 300 patients with BCR-ABL positive leukemias treated with imatinib in a single center: a 4.5 years follow up. Cancer. 2005;103:1659\u201369. doi: 10.1002\/cncr.20922 .","journal-title":"Cancer"},{"issue":"11","key":"230_CR9","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1056\/NEJMoa022457","volume":"348","author":"SG O\u2019Brien","year":"2003","unstructured":"O\u2019Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348(11):994\u20131004.","journal-title":"N Engl J Med"},{"issue":"9","key":"230_CR10","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1056\/NEJMoa011573","volume":"346","author":"H Kantarjian","year":"2002","unstructured":"Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002;346(9):645\u201352.","journal-title":"N Engl J Med"},{"key":"230_CR11","doi-asserted-by":"publisher","first-page":"3530","DOI":"10.1182\/blood.V99.10.3530","volume":"99","author":"C Sawyers","year":"2002","unstructured":"Sawyers C, Hochhaus A, Feldman E, Goldman J, Miller C, Ottomann O. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood. 2002;99:3530\u20139. doi: 10.1182\/blood.V99.10.3530 .","journal-title":"Blood"},{"key":"230_CR12","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1182\/blood.V99.6.1928","volume":"99","author":"M Talpaz","year":"2002","unstructured":"Talpaz M, Silver R, Druker B, Goldman J, Gambacorti-Passerini C, Guilhot F. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood. 2002;99:1928\u201337. doi: 10.1182\/blood.V99.6.1928 .","journal-title":"Blood"},{"key":"230_CR13","first-page":"290","volume":"53","author":"C Deshmukh","year":"2005","unstructured":"Deshmukh C, Saikia T, Bakshi A, Amare Kadam P, Baisnae C, Parikh P. Imatinib mesylate in chronic myeloid leukemia: a prospective, single arm, non-randomized study. J Assoc Physicians India. 2005;53:290\u20135.","journal-title":"J Assoc Physicians India"},{"issue":"6","key":"230_CR14","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1002\/cncr.21756","volume":"106","author":"JE Cortes","year":"2006","unstructured":"Cortes JE, Talpaz M, O\u2019Brien S, et al. Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal. Cancer. 2006;106(6):1306\u201315.","journal-title":"Cancer"},{"issue":"10","key":"230_CR15","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1002\/cncr.21032","volume":"103","author":"H Kantarjian","year":"2005","unstructured":"Kantarjian H, Talpaz M, O\u2019Brien S, et al. Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia\u2014comparison with historic experience. Cancer. 2005;103(10):2099\u2013108.","journal-title":"Cancer"},{"issue":"1","key":"230_CR16","first-page":"5","volume":"22","author":"C Hao","year":"2001","unstructured":"Hao C, Wang Y, Li Q. Multivariate analysis of prognostic factors in Philadelphia chromosome-positive chronic granulocytic leukaemia. Zhonghua Xue Ye Xue Za Zhi. 2001;22(1):5\u20138.","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"7","key":"230_CR17","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1182\/blood-2004-02-0711","volume":"104","author":"HM Kantarjian","year":"2004","unstructured":"Kantarjian HM, Cortes JE, O\u2019Brien S, et al. Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha. Blood. 2004;104(7):1979\u201388.","journal-title":"Blood"},{"issue":"7","key":"230_CR18","first-page":"542","volume":"24","author":"X Lu","year":"2005","unstructured":"Lu X, Zhu J, Li Y. Imatinib in treatment of advanced stage chromosome positive chronic myelocytic leukaemia. Zhongguo Xinyao Yu Linchuang Za Zhi. 2005;24(7):542\u20136.","journal-title":"Zhongguo Xinyao Yu Linchuang Za Zhi"},{"issue":"Suppl 1","key":"230_CR19","first-page":"65aS","volume":"91","author":"C Chuah","year":"2006","unstructured":"Chuah C, Goh Y, Lee L, Koh L, Loh Y. Abl kinase domain mutations are important mechanisms of resistance in Asian patients with imatinib-resistant chronic myeloid leukaemia. Haematologica. 2006;91(Suppl 1):65aS\u20136aS.","journal-title":"Haematologica"},{"key":"230_CR20","doi-asserted-by":"publisher","unstructured":"Hochhaus A, Erben P, Ernst T, Mueller MC. Resistance to targeted therapy in chronic myelogenous leukemia. Semin Hematol 2007;44 Suppl 1(1):S15\u201324. doi: 10.1053\/j.seminhematol.2006.12.002.","DOI":"10.1053\/j.seminhematol.2006.12.002."},{"issue":"5","key":"230_CR21","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1007\/s00277-003-0810-2","volume":"83","author":"L Koh","year":"2004","unstructured":"Koh L, Hwang W, Tan C, Linn Y, Goh Y, Chuah C. Long term follow-up of Asian patients with chronic myeloid leukaemia (CML) receiving allogeneic hematopoietic stem cell transplantation (HSCT) from HLA-identical sibling-evaluation of risks and benefits. Ann Hematol. 2004;83(5):286\u201394. doi: 10.1007\/s00277-003-0810-2 .","journal-title":"Ann Hematol"},{"issue":"23","key":"230_CR22","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O\u2019Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355(23):2408\u201317.","journal-title":"N Engl J Med"},{"issue":"7","key":"230_CR23","first-page":"344","volume":"17","author":"S Wan","year":"1996","unstructured":"Wan S, Qian L, Mi G. Evaluation of effectiveness of recombinant interferon-\u03b1 in 48 patients with chronic myeloid leukaemia. Zhonghua Xue Ye Xue Za Zhi. 1996;17(7):344\u20137.","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"1","key":"230_CR24","first-page":"35","volume":"24","author":"Chronic Ganulocytic Leukaemia Cooperative Study Group","year":"2003","unstructured":"Chronic Ganulocytic Leukaemia Cooperative Study Group. Clinical study of Roferon A combined with homoharringtonine in chronic myeloid leukaemia. Zhonghua Xue Ye Xue Za Zhi. 2003;24(1):35\u20136.","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"6","key":"230_CR25","first-page":"346","volume":"18","author":"Cooperative Study Group of Phase III Clinical Trial on Interferon-\u03b11b","year":"1998","unstructured":"Cooperative Study Group of Phase III Clinical Trial on Interferon-\u03b11b. A summary of phase III clinical trial of interferon-\u03b11b in the treatment of chronic myelogenous leukaemia. Zhongguo Shi Yong Nei Ke Za Zhi. 1998;18(6):346\u20137.","journal-title":"Zhongguo Shi Yong Nei Ke Za Zhi"},{"issue":"2","key":"230_CR26","first-page":"108","volume":"7","author":"Cooperative Study Group of Clinical Trial of recombinant Interferon-\u03b12b","year":"2003","unstructured":"Cooperative Study Group of Clinical Trial of recombinant Interferon-\u03b12b. Clinical observations of recombinant interferon-\u03b12b in treatment of chronic myeloid leukemia. BME Clin Med. 2003;7(2):108\u20139.","journal-title":"BME Clin Med"},{"issue":"11","key":"230_CR27","first-page":"681","volume":"22","author":"L Wang","year":"2002","unstructured":"Wang L, Qian L, Li R. Observation of 15 cases of CML receiving combined treatment with interferon-\u03b1 and homoharringtonine. Zhongguo Shiyong Neike Za Zhi. 2002;22(11):681\u20132.","journal-title":"Zhongguo Shiyong Neike Za Zhi"},{"issue":"1","key":"230_CR28","first-page":"36","volume":"12","author":"A Zuo","year":"2003","unstructured":"Zuo A, Mi G. Clinical observation of combination treatment of interferon-\u03b12b, homoharringtonine and hydroxyurea in chronic myeloid leukemia. J Leukemia Lymphoma. 2003;12(1):36\u20137.","journal-title":"J Leukemia Lymphoma"},{"issue":"1","key":"230_CR29","first-page":"8","volume":"15","author":"X Liu","year":"2002","unstructured":"Liu X, Sun Z, Zhu W. Treatment of interferon alfa-2b combined with low-dose cytarabine in chronic myelogenous leukemia. J Clin Hematol. 2002;15(1):8\u201310.","journal-title":"J Clin Hematol"},{"issue":"10","key":"230_CR30","first-page":"702","volume":"34","author":"L Yang","year":"1995","unstructured":"Yang L, Hou R, Qiao Z. Observation of the combination treatment effect of hydroxyurea and interferon \u03b1 in chronic myelogenous leukaemia. Zhonghua Nei Ke Za Zhi. 1995;34(10):702\u20133.","journal-title":"Zhonghua Nei Ke Za Zhi"},{"issue":"10","key":"230_CR31","first-page":"1293","volume":"14","author":"H Luo","year":"2005","unstructured":"Luo H, Zhong Y, Guan Y. Clinical analysis of imatinib treatment in chronic myeloid leukaemia. Xiandai Zhong Xi Yi Jiehe Za Zhi. 2005;14(10):1293\u20134.","journal-title":"Xiandai Zhong Xi Yi Jiehe Za Zhi"},{"issue":"3","key":"230_CR32","first-page":"154","volume":"18","author":"X Yao","year":"2007","unstructured":"Yao X, Liu C. The application of STI571 in patients with chronic myelogenous leukaemia treated before allogeneic peripheral blood stem cell transplantation. Linchuang Xue Ye Xue Za Zhi. 2007;18(3):154\u20138.","journal-title":"Linchuang Xue Ye Xue Za Zhi"},{"issue":"7","key":"230_CR33","first-page":"389","volume":"26","author":"Y He","year":"2005","unstructured":"He Y, Feng S, Wang M. HLA-identical sibling allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukaemia in first chronic phase. Analysis of 51 cases. Zhonghua Xue Ye Xue Za Zhi. 2005;26(7):389\u201392.","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"3","key":"230_CR34","first-page":"175","volume":"13","author":"Y Wei","year":"2000","unstructured":"Wei Y, Ou Y, Da W. Analysis of HLA typing in hematopoietic stem cell transplantation donors and recipients. Zhongguo Shuxue Zazhi. 2000;13(3):175\u20136.","journal-title":"Zhongguo Shuxue Zazhi"},{"issue":"2","key":"230_CR35","first-page":"55","volume":"16","author":"F Kong","year":"1995","unstructured":"Kong F, Jin L, Chen X. Study on choice for bone marrow transplantation donors. Zhonghua Qiguan Yizhi Zazhi. 1995;16(2):55\u20137.","journal-title":"Zhonghua Qiguan Yizhi Zazhi"},{"issue":"8","key":"230_CR36","first-page":"408","volume":"22","author":"S Ji","year":"2001","unstructured":"Ji S, Chen H, Wang H. Preliminary study of HLA haplotype matched and T-cell undepleted allogeneic bone marrow transplantation for treatment of leukaemia. Zhonghua Xue Ye Xue Za Zhi. 2001;22(8):408\u201310.","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"3","key":"230_CR37","first-page":"119","volume":"11","author":"R Yu","year":"2005","unstructured":"Yu R, Zhou Y, Shen J. Treatment of CML with HLA haploidentical related bone marrow transplantation: report of four cases and literature review. Neike Ji Wei Zhong Zheng Za Zhi. 2005;11(3):119\u201321.","journal-title":"Neike Ji Wei Zhong Zheng Za Zhi"},{"issue":"Suppl 2","key":"230_CR38","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/BF03165081","volume":"76","author":"JE Sanders","year":"2002","unstructured":"Sanders JE. Chronic graft-versus-host disease and late effects after hematopoietic stem cell transplantation. Int J Hematol. 2002;76(Suppl 2):15\u201328.","journal-title":"Int J Hematol"},{"issue":"2","key":"230_CR39","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1002\/hpm.662","volume":"17","author":"P Yip","year":"2002","unstructured":"Yip P, Law C. Assessment of the future resources and needs for hospitalization in Hong Kong SAR (Special Administrative District). Int J Health Plann Manage. 2002;17(2):113\u201322. doi: 10.1002\/hpm.662 .","journal-title":"Int J Health Plann Manage"},{"issue":"3","key":"230_CR40","first-page":"ECR18","volume":"90","author":"W Au","year":"2005","unstructured":"Au W, Lee J. Imatinib mesylate (STI-571) and porphyria cutanea tarda in a Chinese patient. Haematologica. 2005;90(3):ECR18.","journal-title":"Haematologica"},{"issue":"6","key":"230_CR41","doi-asserted-by":"publisher","first-page":"567","DOI":"10.2217\/14622416.8.6.567","volume":"8","author":"S Lal","year":"2007","unstructured":"Lal S, Wong ZW, Jada SR, et al. Novel SLC22A16 polymorphisms and influence on doxorubicin pharmacokinetics in Asian breast cancer patients. Pharmacogenomics. 2007;8(6):567\u201375. doi: 10.2217\/14622416.8.6.567 .","journal-title":"Pharmacogenomics"},{"issue":"3","key":"230_CR42","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/sj.clpt.6100482","volume":"84","author":"SP Myrand","year":"2008","unstructured":"Myrand SP, Sekiguchi K, Man MZ, et al. Pharmacokinetics\/genotype associations for major cytochrome P450 enzymes in native and first- and third-generation Japanese populations: comparison with Korean, Chinese, and Caucasian populations. Clin Pharmacol Ther. 2008;84(3):347\u201361. doi: 10.1038\/sj.clpt.6100482 .","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"230_CR43","first-page":"494","volume":"110","author":"R Liang","year":"1997","unstructured":"Liang R, Lee C, Chen F, Kwong Y, Chim C, Au W. Unrelated marrow donor registry for Chinese. Chin Med J. 1997;110(6):494\u20136.","journal-title":"Chin Med J"},{"issue":"1","key":"230_CR44","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","volume":"108","author":"T Hughes","year":"2006","unstructured":"Hughes T, Deininger M, Hochhaus A, Branford S, Radish J, Kaeda J. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006;108(1):28\u201337. doi: 10.1182\/blood-2006-01-0092 .","journal-title":"Blood"},{"key":"230_CR45","first-page":"659","volume":"91","author":"H Kang","year":"2006","unstructured":"Kang H, Hwang J, Kim S, Goh H, Kim M, Kim D. Comparison of allele specific oligonucleotide-polymerase chain reaction and direct sequencing for high throughput screening of ABL kinase domain mutations in chronic myeloid leukemia resistant to imatinib. Haematologica. 2006;91:659\u201362.","journal-title":"Haematologica"},{"key":"230_CR46","doi-asserted-by":"crossref","unstructured":"Druker B, Guilhot F, O\u2019Brien S, Larson R. Long-term benefits of imatinib for patients newly diagnosed with chronic myelogenous leukemia in chronic phase: the 5-year update from the IRIS study. Abstract presented at ASCO 2006; 2006.","DOI":"10.1200\/jco.2006.24.18_suppl.6506"},{"issue":"18","key":"230_CR47","doi-asserted-by":"crossref","first-page":"A6506","DOI":"10.1200\/jco.2006.24.18_suppl.6506","volume":"24","author":"J Druker","year":"2006","unstructured":"Druker J, Guilhot F, O\u2019Brien S, Larson RA. IRIS. Long-term benefits of imatinib (IM) for patients newly diagnosed with chronic myelogenous leukemia in chronic phase (CML-CP): the 5-year update from the IRIS study. J Clin Oncol. 2006;24(18):A6506.","journal-title":"J Clin Oncol"},{"key":"230_CR48","volume-title":"SEER Cancer statistics review, 1975\u20132003","author":"L Ries","year":"2007","unstructured":"Ries L, Harkins D, Krapcho M. SEER Cancer statistics review, 1975\u20132003. Bethesda: National Cancer Institute; 2007."},{"key":"230_CR49","first-page":"3","volume":"13","author":"Q He","year":"1993","unstructured":"He Q, Shi F, Yuan Z. Epidemiological survey of leukaemia in Baotou city. Neimenggu Yi Xue Za Zhi. 1993;13:3\u20135.","journal-title":"Neimenggu Yi Xue Za Zhi"},{"issue":"7","key":"230_CR50","first-page":"347","volume":"22","author":"X Zhang","year":"2001","unstructured":"Zhang X, Liu H, Zhang D. Epidemiological survey of leukaemia and aplastic anemia in Shenzhen special economic zone. Zhonghua Xue Ye Xue Za Zhi. 2001;22(7):347.","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"1","key":"230_CR51","first-page":"114","volume":"18","author":"J Hu","year":"2004","unstructured":"Hu J, Mo Z, Dong Q. A 15-year epidemiological survey of leukaemia in Haian County. Zhongguo Jiaotong Yi Xue Za Zhi. 2004;18(1):114\u20135.","journal-title":"Zhongguo Jiaotong Yi Xue Za Zhi"},{"issue":"8","key":"230_CR52","first-page":"430","volume":"15","author":"Z Tang","year":"1994","unstructured":"Tang Z, Sun Q, Zhang J. An 11-year epidemiological survey of leukaemia in Jinshan County, Shanghai City. Zhonghua Xue Ye Xue Za Zhi. 1994;15(8):430.","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"230_CR53","volume-title":"Two year report of the population based cancer registries 1999\u20132000","author":"National Cancer Registry Programme","year":"2005","unstructured":"National Cancer Registry Programme. Two year report of the population based cancer registries 1999\u20132000. New Delhi: Indian Council of Medical Research; 2005."},{"key":"230_CR54","volume-title":"Trends in cancer incidence in Singapore 1968\u20132002. Singapore Cancer Registry Report No. 6","author":"A Seow","year":"2004","unstructured":"Seow A, Koh W, Chia K, Shi L, Lee H. Trends in cancer incidence in Singapore 1968\u20132002. Singapore Cancer Registry Report No. 6. Singapore: Singapore Cancer Registry; 2004."},{"key":"230_CR55","first-page":"662","volume":"73","author":"S Jootar","year":"1990","unstructured":"Jootar S, Chuncharunee S, Ongphiphadhanakul B, Atichartakarn V. Multivariate analysis of prognostic factors in Philadelphia chromosome positive chronic myeloid leukemia. J Med Assoc Thai. 1990;73:662\u20139.","journal-title":"J Med Assoc Thai"},{"key":"230_CR56","first-page":"25","volume":"14","author":"S Jootar","year":"1996","unstructured":"Jootar S, Ungkanont A, Chuncharunee S, Atichartakarn V. Multivariate analysis of prognostic factors in Philadelphia chromosome positive chronic myeloid leukemia: an update of the first series in Thailand. Asian Pac J Allergy Immunol. 1996;14:25\u201330.","journal-title":"Asian Pac J Allergy Immunol"},{"key":"230_CR57","volume-title":"Cancer incidence in five continents, vol IX","author":"M Curado","year":"2007","unstructured":"Curado M, Edwards B, Shin H, Storm H, Ferlay J, Heanue M, et al. Cancer incidence in five continents, vol IX. Lyon: IARC Scientific Publications; 2007."},{"key":"230_CR58","unstructured":"Caguioa PB. CML incidence relative to all leukemias in the Philippines. 2007. Personal Communication."}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-008-0230-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-008-0230-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s12185-008-0230-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-008-0230-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T09:39:43Z","timestamp":1632821983000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-008-0230-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12,20]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1]]}},"alternative-id":["230"],"URL":"https:\/\/doi.org\/10.1007\/s12185-008-0230-0","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,12,20]]}}}